Targanta Therapeutics Corporation announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for its lead candidate, oritavancin, a novel semi-synthetic lipoglycopeptide antibiotic candidate with potent bactericidal activity against a broad spectrum of gram-positive bacteria.
Targanta submits Marketing Authorization Application for oritavancin